Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

被引：7

作者：

Woodford, Rachel ^{[1
]}

Loh, Yanni ^{[1
]}

Lee, Joanna ^{[1
]}

Cooper, Wendy ^{[2
,3
,4
]}

Marschner, Ian ^{[5
,6
]}

Lewis, Craig R. ^{[7
]}

Millward, Michael ^{[8
,9
]}

Lord, Sally ^{[5
,10
]}

Gralla, Richard J. ^{[11
]}

Yang, James C-H ^{[12
,13
]}

Mok, Tony ^{[14
]}

Lee, Chee K. ^{[1
,5
]}

机构：

[1] St George Hosp, Canc Care Ctr, Sydney, NSW 2217, Australia

[2] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW 2050, Australia

[3] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia

[4] Western Sydney Univ, Sch Med, Sydney, NSW 2751, Australia

[5] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 1450, Australia

[6] Macquarie Univ, Dept Stat, Sydney, NSW 2109, Australia

[7] Univ NSW, Prince Wales Hosp, Clin Sch, Sydney, NSW 2031, Australia

[8] Univ Western Australia, Sch Med, Perth, WA 6009, Australia

[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA 6010, Australia

[10] Univ Notre Dame, Sch Med, Sydney, NSW 2010, Australia

[11] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10461 USA

[12] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10002, Taiwan

[13] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan

[14] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 20期

关键词：

chemoimmunotherapy; meta-analysis; non-small-cell lung cancer; PD-L1; expression; progression-free survival; AMERICAN SOCIETY; SQUAMOUS-CELL; OPEN-LABEL; NIVOLUMAB; CHEMOTHERAPY; DOCETAXEL; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; MECHANISMS; PHASE-1;

D O I：

10.2217/fon-2019-0105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

引用

页码：2371 / 2383

页数：13

共 50 条

[41] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer [J].

Meyers, D. E. ;

Bryan, P. M. ;

Banerji, S. ;

Morris, D. G. .

CURRENT ONCOLOGY, 2018, 25 (04) :E324-E334

[42] PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations [J].

Scheel, Andreas H. ;

Ansen, Sascha ;

Schultheis, Anne M. ;

Scheffler, Matthias ;

Fischer, Rieke N. ;

Michels, Sebastian ;

Hellmich, Martin ;

George, Julie ;

Zander, Thomas ;

Brockmann, Michael ;

Stoelben, Erich ;

Groen, Harry ;

Timens, Wim ;

Perner, Sven ;

von Bergwelt-Baildon, Michael ;

Buettner, Reinhard ;

Wolf, Juergen .

ONCOIMMUNOLOGY, 2016, 5 (05)

[43] Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer [J].

Cheng, Yuxin ;

Wang, Ting ;

Lv, Xin ;

Li, Rutian ;

Yuan, Ling ;

Shen, Jie ;

Li, Yan ;

Yan, Tingting ;

Liu, Baorui ;

Wang, Lifeng .

CANCER MANAGEMENT AND RESEARCH, 2020, 12 :2069-2078

[44] Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer [J].

Kim, C. G. ;

Kim, K. H. ;

Pyo, K-H ;

Xin, C-F ;

Hong, M. H. ;

Ahn, B-C ;

Kim, Y. ;

Choi, S. J. ;

Yoon, H., I ;

Lee, J. G. ;

Lee, C. Y. ;

Park, S. Y. ;

Park, S-H ;

Cho, B. C. ;

Shim, H. S. ;

Shin, E-C ;

Kim, H. R. .

ANNALS OF ONCOLOGY, 2019, 30 (07) :1104-1113

[45] Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors [J].

Jiang, Tao ;

Bai, Yuchen ;

Zhou, Fei ;

Li, Wei ;

Gao, Guanghui ;

Su, Chunxia ;

Ren, Shengxiang ;

Chen, Xiaoxia ;

Zhou, Caicun .

LUNG CANCER, 2019, 130 :76-83

[46] Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin [J].

Qiu, Yajuan ;

Jiang, Junguang ;

Zhang, Mingzhi ;

Qin, Yanru .

ONCOLOGY LETTERS, 2019, 18 (01) :161-168

[47] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer [J].

Shankar, Bairavi ;

Naidoo, Jarushka .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S4034-S4037

[48] The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients [J].

Jin, Huibin ;

Hu, Bingxin ;

Zhang, Jie ;

Long, Ye ;

Xuan, Ang ;

Wu, Xinyu ;

Xu, Junling ;

Gao, Yongju .

FRONTIERS IN ONCOLOGY, 2025, 15

[49] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer [J].

Sakamoto, Mandy ;

Jimeno, Antonio .

DRUGS OF TODAY, 2023, 59 (03) :169-177

[50] What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough? [J].

Bilgin, Burak ;

Yucel, Sebnem ;

Sendur, Mehmet Ali Nahit ;

Yalcin, Bulent .

FUTURE ONCOLOGY, 2024, 20 (38) :3039-3041

← 1 2 3 4 5 →